GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Equity-to-Asset

Philogen SpA (STU:78Q) Equity-to-Asset : 0.82 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Philogen SpA's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €138.66 Mil. Philogen SpA's Total Assets for the quarter that ended in Dec. 2024 was €168.45 Mil. Therefore, Philogen SpA's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.82.

The historical rank and industry rank for Philogen SpA's Equity-to-Asset or its related term are showing as below:

STU:78Q' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.65   Med: 0.78   Max: 0.82
Current: 0.82

During the past 5 years, the highest Equity to Asset Ratio of Philogen SpA was 0.82. The lowest was 0.65. And the median was 0.78.

STU:78Q's Equity-to-Asset is ranked better than
70.1% of 1485 companies
in the Biotechnology industry
Industry Median: 0.68 vs STU:78Q: 0.82

Philogen SpA Equity-to-Asset Historical Data

The historical data trend for Philogen SpA's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Equity-to-Asset Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
0.65 0.79 0.78 0.76 0.82

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.78 0.76 0.72 0.82

Competitive Comparison of Philogen SpA's Equity-to-Asset

For the Biotechnology subindustry, Philogen SpA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Philogen SpA's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Philogen SpA's Equity-to-Asset falls into.


;
;

Philogen SpA Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Philogen SpA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=138.657/168.452
=0.82

Philogen SpA's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=138.657/168.452
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Philogen SpA  (STU:78Q) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Philogen SpA Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Philogen SpA's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Philogen SpA Business Description

Traded in Other Exchanges
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines